ArticleScientific reports2026
Insights into the antibacterial mode of action of cress polysaccharide-mediated NiO nanoparticles.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The increasing prevalence of antimicrobial resistance necessitates the development of alternative antibacterial strategies. In this study, nickel oxide nanoparticles (NiO NPs) were synthesized using cress (Lepidium sativum) seed mucilage polysaccharides (CSP) as a green reducing and stabilizing agent. The formation of CSP-mediated NiO nanoparticles (CSP-NiO) was confirmed through extensive characterization using UV-Visible, FTIR, XRD, SEM, and EDX techniques. The CSP-NiO NPs exhibited minimal erythrocyte toxicity (< 5% hemolysis at 200 µg/mL) and dose-dependent antibacterial activity against Gram-positive (Staphylococcus aureus and Clostridium tetani) and Gram-negative (Escherichia coli and Klebsiella pneumoniae) bacteria, with MIC values ranging from 25 to 50 µg/mL. The mechanistic investigations revealed increased intracellular reactive oxygen species (ROS) production, membrane disruption (evidenced by protein leakage), and genomic DNA damage in treated bacterial cells. These findings suggest that CSP-NiO NPs exert antibacterial effects through oxidative stress, leading to membrane disruption and genomic DNA damage, thereby establishing them as a sustainable nanomaterial platform for future antimicrobial applications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.